<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0301-696X</journal-id>
<journal-title><![CDATA[Revista de sanidad militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. sanid. mil.]]></abbrev-journal-title>
<issn>0301-696X</issn>
<publisher>
<publisher-name><![CDATA[Secretaría de la Defensa Nacional, Dirección General de Sanidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0301-696X2024000100002</article-id>
<article-id pub-id-type="doi">10.56443/agm64g31</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Effect of co-treatment of COVID-19 with Remdesivir]]></article-title>
<article-title xml:lang="es"><![CDATA[Efecto del cotratamiento de COVID-19 con Remdesivir]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Araiza]]></surname>
<given-names><![CDATA[Mayra Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Cuazitl]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Mezquita]]></surname>
<given-names><![CDATA[Dante José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeyda-Farfán]]></surname>
<given-names><![CDATA[José Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrón-Campos]]></surname>
<given-names><![CDATA[Arcelia Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez-Velasco]]></surname>
<given-names><![CDATA[Arleth Sarai]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Salazar]]></surname>
<given-names><![CDATA[Iván Noé]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaria de la Defensa Nacional Hospital Cetral Militar ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Secretaria de la Defensa Nacional Escuela Militar de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>78</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0301-696X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0301-696X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0301-696X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Due to the COVID-19 pandemic, randomized clinical studies were conducted with Remdesivir in combination with Bariticinib or Dexamethasone, which have shown effectiveness for the treatment of COVID-19.  Objective:  We analyzed the effect of co-treatment with Remdesivir in a retrospective in Mexico.  Methods:  Thirty-four patients treated with Remdesivir in combination with Baricitinib or Dexamethasone were included. Age, sex, comorbidities, signs, and symptoms were recorded at hospital admission, intubation needs, intensive care unit (ICU) requirements, days of hospital stay and their evolution, as well as laboratory data upon admission and upon admission terminate Remdesivir treatment.  Results:  Most were male, with an age of 56.5 years (49 years-60.3 years), whose main comorbidity was obesity. The main symptoms on admission were dyspnea and cough. Thirty-two patients received the short Remdesivir regimen, 22 were co-treated with Baricitinb and 12 with Dexamethasone. Most did not require ICU care, 9 patients died, 19% of those co-treated with Baricitinib and 42% of those co-treated with Dexamethasone. A significant decrease in hemoglobin, protein, albumin and LDH levels was observed.  Conclusion:  In this study, we observed lower mortality in patients co-treated with Baricitinib vs those co-treated with Dexamethasone, and a hospital stay similar to that reported in randomized clinical studies.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Debido a la pandemia de COVID-19, se realizaron estudios clínicos aleatorizados con Remdesivir en combinación con Bariticinib o Dexametasona, que han demostrado efectividad para el tratamiento de COVID-19.  Objetivo:  Se realizo un análisis del efecto del co-tratamiento con Remdesivir en una muestra retrospectiva en México.  Métodos:  Se incluyeron 34 pacientes tratados con Remdesivir en combinación con Baricitinib o Dexametasona. Se registraron edad, sexo, comorbilidades, signos y síntomas al ingreso hospitalario, necesidades de intubación, requerimientos de unidad de cuidados intensivos (UCI), días de estancia hospitalaria y su evolución, así como datos de laboratorio al ingreso y al ingreso al final del tratamiento con Remdesivir.  Resultados:  La mayoría eran varones, con una edad de 56.5 años (49 años-60.3 años), cuya principal comorbilidad era la obesidad. Los principales síntomas al ingreso fueron disnea y tos. Treinta y dos pacientes recibieron el régimen corto de Remdesivir, 22 fueron cotratados con Baricitinb y 12 con Dexametasona. La mayoría no requirió atención en UCI, 9 pacientes fallecieron, 19% de los cotratados con Baricitinib y 42% de los cotratados con Dexametasona. Se observó una disminución significativa en los niveles de hemoglobina, proteínas, albúmina y LDH.  Conclusión:  En este estudio observamos una menor mortalidad en los pacientes cotratados con Baricitinib frente a los cotratados con Dexametasona, y una estancia hospitalaria similar a la reportada en estudios clínicos aleatorizados.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[Remdesivir]]></kwd>
<kwd lng="en"><![CDATA[Baricitinib]]></kwd>
<kwd lng="en"><![CDATA[Dexamethasone]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[remdesivir]]></kwd>
<kwd lng="es"><![CDATA[baricitinib]]></kwd>
<kwd lng="es"><![CDATA[Dexametasona]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiersinga]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Prescott]]></surname>
<given-names><![CDATA[HC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>324</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>782-93</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elsawah]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Elsokary]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdallah]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[ElShafie]]></surname>
<given-names><![CDATA[AH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis]]></article-title>
<source><![CDATA[Rev Med Virol]]></source>
<year>2021</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murgolo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Therien]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Koeplinger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development]]></article-title>
<source><![CDATA[PLoS Pathog]]></source>
<year>2021</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrucci]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[D-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Asadzadeh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Marrone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boccia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Siciliano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-chain polyphosphates impair SARS-CoV-2 infection and replication]]></article-title>
<source><![CDATA[Sci Signal]]></source>
<year>2021</year>
<volume>14</volume>
<numero>690</numero>
<issue>690</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piscoya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ng-Sueng]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Parra Del Riego]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cerna-Viacava]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pasupuleti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2020</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trougakos]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Stamatelopoulos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Terpos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tsitsilonis]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
<name>
<surname><![CDATA[Aivalioti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Paraskevis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications]]></article-title>
<source><![CDATA[Journal of Biomedical Science]]></source>
<year>2021</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Eijk]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Binkhorst]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgonje]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Offringa]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Mulder]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19: immunopathology, pathophysiological mechanisms, and treatment options]]></article-title>
<source><![CDATA[J Pathol]]></source>
<year>2021</year>
<volume>254</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>307-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beigel]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Tomashek]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Dodd]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Zingman]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Kalil]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remdesivir for the Treatment of Covid-19 - Final Report]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2020</year>
<volume>383</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1813-26</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[P-L]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[N-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cia]]></surname>
<given-names><![CDATA[C-T]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[W-C]]></given-names>
</name>
<name>
<surname><![CDATA[Hsueh]]></surname>
<given-names><![CDATA[P-R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs]]></article-title>
<source><![CDATA[Frontiers in Pharmacology]]></source>
<year>2020</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Secretaria de Salud</collab>
<collab>Comisión Federal para la Protección de Riesgos Sanitarios</collab>
<source><![CDATA[Comunicado a la Población 12 de marzo de 2021]]></source>
<year>2021</year>
<publisher-name><![CDATA[Gobierno de Mexico]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>U.S. Food &amp; Drung Admistration</collab>
<source><![CDATA[FDA Approves First Treatment for COVID-19]]></source>
<year>2021</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
<publisher-name><![CDATA[U.S. Food &amp; Drung Admistration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garibaldi]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Zeger]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Bandeen-Roche]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19]]></article-title>
<source><![CDATA[JAMA network open]]></source>
<year>2021</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>U.S. Food &amp; Drung Admistration</collab>
<source><![CDATA[Actualización sobre el coronavirus (COVID-19): La FDA autoriza una combinación de medicamentos para el tratamiento del COVID-19]]></source>
<year>2020</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
<publisher-name><![CDATA[U.S. Food &amp; Drung Admistration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<collab>The RECOVERY Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Dexamethasone in Hospitalized Patients with Covid-19]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2021</year>
<volume>384</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>693-704</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>National Institutes of Health</collab>
<source><![CDATA[Clinical Spectrum of SARS-CoV-2 Infection]]></source>
<year>2021</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
<publisher-name><![CDATA[National Institutes of Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Hospital MG</collab>
<source><![CDATA[Massachusetts General Hospital COVID-19 Treatment Guidance]]></source>
<year>2020</year>
<publisher-loc><![CDATA[MA ]]></publisher-loc>
<publisher-name><![CDATA[Massachusetts General Hospital Boston]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Consejo Interistitucional</collab>
<source><![CDATA[Guía clínica para el tratamiento de la COVID-19 en México]]></source>
<year>2021</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Gobierno]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalil]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Tomashek]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfe]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ghazaryan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2021</year>
<volume>384</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>795-807</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Butler-Laporte]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Brophy]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2021</year>
<volume>104</volume>
<page-range>671-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[M-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[X-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X-F]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[P-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia]]></article-title>
<source><![CDATA[Respir Res]]></source>
<year>2020</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>171</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
